The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that work by stimulating the tibial nerve.

The company unveiled the appointment alongside news of the departure of its chief commercial officer.

Edwards terminated the deal after the Federal Trade Commission moved to block the acquisition due to anticompetitive concerns ...

From insurance coverage questions to M&A and tariffs, here are the top storylines to watch in the medical device space in ...

Johnson & Johnson’s filing comes a month after Medtronic gained U.S. clearance for its Hugo system as competition in the soft ...

In a pair of guidance documents released Tuesday, the regulator clarified the types of wellness features and clinical ...

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular ...

CMR Surgical received the approval for abdominal surgery for its Versius platform in patients under age 18 in Europe, while ...

The China-based surgical robot manufacturer is gearing up for growth after receiving Europe’s CE mark last year for its ...

Stanley Bergman has worked at Henry Schein for 45 years, more than 35 of which he spent as CEO, and was due to retire at the ...

Executives at companies innovating a range of new robotic surgery platforms shared their progress and challenges in MedTech ...

The company will use the money to try to establish its cuffless device as a go-to option for 24-hour blood pressure ...